Treatment of Myocarditis and Stress Cardiomyopathy
For myocarditis, treat with standard heart failure medications (ACE inhibitors/ARBs, beta-blockers, diuretics) and consider immunosuppression only for specific non-viral causes like giant cell myocarditis or cardiac sarcoidosis; for stress cardiomyopathy (takotsubo), use supportive care with ACE inhibitors/ARBs and cautious beta-blocker use, avoiding them in the presence of left ventricular outflow tract obstruction or severe bradycardia. 1, 2
Myocarditis Treatment
Acute Phase Management
The treatment approach depends on the underlying cause, which varies by region. In North America and Western Europe, viral infections (particularly parvovirus B19, human herpes virus 6, and Coxsackie B) are the most common causes 1.
Standard heart failure therapy includes:
- ACE inhibitors or ARBs
- Beta-blockers (use cautiously if QTc >500 ms due to torsades de pointes risk)
- Diuretics for volume overload
- Supportive care based on clinical presentation 1
Immunosuppression - When to Use
Critical distinction: Immunosuppression is NOT indicated for viral myocarditis. Reserve it for specific non-infectious causes 1:
- Giant cell myocarditis: Requires aggressive multidrug immunosuppression plus advanced heart failure treatment (rapidly fatal without intervention)
- Cardiac sarcoidosis: Corticosteroids are first-line; alternative agents (methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide) for steroid-intolerant patients or those worsening despite steroids
- Subacute/early chronic DCM with active inflammation: A minority may improve with immunosuppression 1
Device Therapy
ICD implantation is reasonable for cardiac sarcoidosis patients 1.
Common pitfall: Do not use immunosuppression empirically for presumed viral myocarditis—it may worsen outcomes. Endomyocardial biopsy can help distinguish infectious from non-infectious causes when immunosuppression is being considered.
Stress Cardiomyopathy (Takotsubo) Treatment
Acute Phase Management
The cornerstone is supportive care tailored to hemodynamic status 2:
For patients WITHOUT left ventricular outflow tract obstruction (LVOTO):
- ACE inhibitors or ARBs (facilitate LV recovery)
- Diuretics for pulmonary edema
- Nitroglycerin to reduce filling pressures and afterload
- Beta-blockers may be used cautiously 2
For patients WITH LVOTO:
- Avoid nitroglycerin (worsens pressure gradient)
- Avoid inotropes (worsen obstruction)
- Beta-blockers may improve LVOTO, but contraindicated if severe heart failure with low LVEF, hypotension, or bradycardia
- Consider ivabradine (If channel inhibitor) as alternative 2
Critical Safety Considerations
- Beta-blockers: Use cautiously, especially with bradycardia and QTc >500 ms (risk of pause-dependent torsades de pointes) 2
- Avoid QT-prolonging drugs in acute phase due to arrhythmia risk 2
- Levosimendan (Ca2+-sensitizer) may be safer alternative to catecholamine inotropes when inotropic support needed 2
Anticoagulation
For severe LV dysfunction with apical ballooning, consider anticoagulation (IV/subcutaneous heparin acutely, then oral anticoagulation or antiplatelet therapy) due to LV thrombus risk and systemic embolism potential 2.
Arrhythmia Management
- Temporary transvenous pacemaker for hemodynamically significant bradycardia
- Wearable defibrillator (life vest) for excessive QT prolongation or life-threatening ventricular arrhythmias
- Do not implant permanent ICD during acute phase—dysfunction is reversible 2
Long-Term Management
ACE inhibitors or ARBs are associated with improved outcomes and may reduce recurrence risk 2, 3. The optimal duration of therapy remains uncertain since this is a transient disorder with 95% full recovery rate 3, 4.
Key distinction from myocarditis: Takotsubo is stress-induced and reversible, typically recovering completely within weeks to months, whereas myocarditis may progress to chronic dilated cardiomyopathy 1, 2.